AU6985900A - Use of n-acetyl-cysteine in the manufacture of topical pharmaceutical compositions for the treatment of allergic pathologies of the respiratory tract - Google Patents

Use of n-acetyl-cysteine in the manufacture of topical pharmaceutical compositions for the treatment of allergic pathologies of the respiratory tract

Info

Publication number
AU6985900A
AU6985900A AU69859/00A AU6985900A AU6985900A AU 6985900 A AU6985900 A AU 6985900A AU 69859/00 A AU69859/00 A AU 69859/00A AU 6985900 A AU6985900 A AU 6985900A AU 6985900 A AU6985900 A AU 6985900A
Authority
AU
Australia
Prior art keywords
cysteine
acetyl
manufacture
treatment
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69859/00A
Inventor
Francesco Santangelo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon Group SpA
Original Assignee
Zambon Group SpA
Zambon SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Group SpA, Zambon SpA filed Critical Zambon Group SpA
Publication of AU6985900A publication Critical patent/AU6985900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU69859/00A 1999-07-27 2000-07-21 Use of n-acetyl-cysteine in the manufacture of topical pharmaceutical compositions for the treatment of allergic pathologies of the respiratory tract Abandoned AU6985900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI99A1653 1999-07-27
IT1999MI001653A IT1313567B1 (en) 1999-07-27 1999-07-27 USE OF N-ACETYL-CISTEIN FOR THE PREPARATION OF TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ALLERGIC PATHOLOGIES OF
PCT/EP2000/007036 WO2001007019A2 (en) 1999-07-27 2000-07-21 Use of n-acetyl-cysteine in the treatment of allergic pathologies of the respiratory tract

Publications (1)

Publication Number Publication Date
AU6985900A true AU6985900A (en) 2001-02-13

Family

ID=11383417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69859/00A Abandoned AU6985900A (en) 1999-07-27 2000-07-21 Use of n-acetyl-cysteine in the manufacture of topical pharmaceutical compositions for the treatment of allergic pathologies of the respiratory tract

Country Status (3)

Country Link
AU (1) AU6985900A (en)
IT (1) IT1313567B1 (en)
WO (1) WO2001007019A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT509045B1 (en) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H COMPOUNDS FOR THE TREATMENT OF ASTHMA BRONCHIALE
IT1405758B1 (en) * 2010-11-03 2014-01-24 Stewart Italia Srl NAC BASED PHARMACEUTICAL PREPARATION IN HYPERTONIC SOLUTION FOR THE TREATMENT OF RINOFARINGEAL AFFECTIONS
ITNA20110020A1 (en) * 2011-05-03 2012-11-04 Gruppo Farmaimpresa Srl NAC AND MSM PHARMACEUTICAL PREPARATION IN SOLUTION FOR THE TREATMENT OF RINOFARINGEAL AFFECTIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA821525A (en) * 1969-08-26 L. Sheffner Aaron N-acetylcysteine containing composition
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
EP0954318A1 (en) * 1996-06-04 1999-11-10 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
WO1998047497A2 (en) * 1997-04-23 1998-10-29 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
JP2001524108A (en) * 1997-04-30 2001-11-27 ワーナー−ランバート・カンパニー Topical nasal anti-inflammatory composition
FR2788436A1 (en) * 1999-01-14 2000-07-21 Pf Medicament Composition useful for treating allergic rhinitis contains phenothiazine derivative in aqueous stabilized with sulfur-containing amino acid derivative

Also Published As

Publication number Publication date
WO2001007019A2 (en) 2001-02-01
WO2001007019A3 (en) 2001-09-27
ITMI991653A1 (en) 2001-01-27
ITMI991653A0 (en) 1999-07-27
IT1313567B1 (en) 2002-09-09

Similar Documents

Publication Publication Date Title
EP1600169A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
EE05404B1 (en) A quinuclidine derivative, its preparation and its use in the preparation of a medicament for the treatment of respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition containing it
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
AU2003233583A1 (en) Oral lactoferrin in the treatment of respiratory disorders
EE200300295A (en) A quinuclidine carbamate derivative, its preparation and its use in the preparation of a medicament for the treatment of respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition containing it.
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
AU2002341558A1 (en) Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
AU2001241162A1 (en) Remedies for allergic diseases
AU6985900A (en) Use of n-acetyl-cysteine in the manufacture of topical pharmaceutical compositions for the treatment of allergic pathologies of the respiratory tract
AU3824800A (en) Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
GB0312566D0 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
AU7703700A (en) Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
AU2002348299A1 (en) Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
CA2436537A1 (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines
AU2002361190A1 (en) Preparation for the topical anaesthesia of the skin
IL150122A0 (en) Remedies for external use for allergic skin diseases
HUP0300876A3 (en) Use of diclofenac for the manufacture of medicament for the topical treatment of burns
AU2003255111A1 (en) The use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention
AU2001282410A1 (en) N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer
AU2001289719A1 (en) Use of anellated dihydropyridines for the preparation of pharmaceutical compositions for the treatment of chronic pain
AU2003229656A1 (en) A pharmaceutical formulation for endonasal administration and its use in the treatment of rhinitic symptoms

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase